Unknown

Dataset Information

0

Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.


ABSTRACT: Tirabrutinib is an irreversible, small-molecule Bruton's tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B-cell malignancies and is in clinical development for inflammatory diseases. As an application of model-informed drug development, a semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for irreversible BTK inhibition of tirabrutinib was developed to support dose selection in clinical development, based on clinical PK and BTK occupancy data from two phase I studies with a wide range of PK exposures in healthy volunteers and in subjects with rheumatoid arthritis. The developed model adequately described and predicted the PK and PD data. Overall, the model-based simulation supported a total daily dose of at least 40 mg, either q.d. or b.i.d., with adequate BTK occupancy (> 90%) for further development in inflammatory diseases. Following the PK/PD modeling and simulation, the relationship between model-predicted BTK occupancy and preliminary clinical efficacy data was also explored and a positive trend was identified between the increasing time above adequate BTK occupancy and better efficacy in treatment for RA by linear regression.

SUBMITTER: Meng A 

PROVIDER: S-EPMC9298258 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.

Meng Amy A   Humeniuk Rita R   Jürgensmeier Juliane M JM   Hsueh Chia-Hsiang CH   Matzkies Franziska F   Grant Ethan E   Truong Hoa H   Billin Andrew N AN   Yu Helen H   Feng Joy J   Kwan Ellen E   Tarnowski Thomas T   Nelson Cara H CH  

Clinical pharmacology and therapeutics 20211027 2


Tirabrutinib is an irreversible, small-molecule Bruton's tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B-cell malignancies and is in clinical development for inflammatory diseases. As an application of model-informed drug development, a semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model for irreversible BTK inhibition of tirabrutinib was developed to support dose selection in clinical development, based on clinical PK and BTK occupancy data from two  ...[more]

Similar Datasets

| S-EPMC5417014 | biostudies-literature
| S-EPMC8092884 | biostudies-literature
| S-EPMC6561755 | biostudies-literature
| S-EPMC11919261 | biostudies-literature
| S-EPMC10345848 | biostudies-literature
| S-EPMC8635024 | biostudies-literature
| S-EPMC10470882 | biostudies-literature
| S-EPMC11652821 | biostudies-literature
| S-EPMC10091729 | biostudies-literature
| S-EPMC11494920 | biostudies-literature